tradingkey.logo

Harvard Bioscience Inc

HBIO
查看詳細走勢圖
0.753USD
-0.014-1.79%
收盤 12/19, 16:00美東報價延遲15分鐘
33.59M總市值
虧損本益比TTM

Harvard Bioscience Inc

0.753
-0.014-1.79%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.79%

5天

+1.70%

1月

+34.15%

6月

+41.72%

今年開始到現在

-64.29%

1年

-64.29%

查看詳細走勢圖

TradingKey Harvard Bioscience Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Harvard Bioscience Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名126/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價2.00。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Harvard Bioscience Inc評分

相關信息

行業排名
126 / 208
全市場排名
295 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
2.000
目標均價
+164.27%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Harvard Bioscience Inc亮點

亮點風險
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
業績增長期
公司處於發展階段,最新年度總收入94.14M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入94.14M美元
估值高估
公司最新PE估值-0.62,處於3年歷史高位
機構減倉
最新機構持股25.97M股,環比減少25.10%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉868.48K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.72

Harvard Bioscience Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Harvard Bioscience Inc簡介

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
公司代碼HBIO
公司Harvard Bioscience Inc
CEODuke (John D)
網址https://www.harvardbioscience.com/

常見問題

Harvard Bioscience Inc(HBIO)的當前股價是多少?

Harvard Bioscience Inc(HBIO)的當前股價是 0.753。

Harvard Bioscience Inc 的股票代碼是什麼?

Harvard Bioscience Inc的股票代碼是HBIO。

Harvard Bioscience Inc股票的52週最高點是多少?

Harvard Bioscience Inc股票的52週最高點是2.280。

Harvard Bioscience Inc股票的52週最低點是多少?

Harvard Bioscience Inc股票的52週最低點是0.281。

Harvard Bioscience Inc的市值是多少?

Harvard Bioscience Inc的市值是33.59M。

Harvard Bioscience Inc的淨利潤是多少?

Harvard Bioscience Inc的淨利潤為-12.40M。

現在Harvard Bioscience Inc(HBIO)的股票是買入、持有還是賣出?

根據分析師評級,Harvard Bioscience Inc(HBIO)的總體評級為買入,目標價格為2.000。

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是多少

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是-1.214。
KeyAI